Status:
UNKNOWN
Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients
Lead Sponsor:
Tongji Hospital
Conditions:
ST Elevation Myocardial Infarction
STEMI
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Neuraminidase-1 can cause the removal of terminal sialic acid residues from the cell surface or serum sialyloconjugates. The level of Neu5Ac was positively related to the activity of neuraminidase-1. ...
Eligibility Criteria
Inclusion
- Between the ages of 18 and 75, regardless of gender;
- STEMI should be diagnosed by two attending physicians or above, including history, clinical symptoms and signs;
- Participate voluntarily and sign informed consent, and can be followed up for more than one month.
Exclusion
- Allergic to oseltamivir;
- Creatinine clearance rate less than 60%;
- Severe liver insufficiency;
- Female patients who have or plan to become pregnant;
- Life expectancy less than one year;
- Patients refused to comply with the requirements of this study;
- According to the discretion of investigator, the patient was unable to complete the study or comply with the requirements of the study (for administrative or other reasons).
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2024
Estimated Enrollment :
382 Patients enrolled
Trial Details
Trial ID
NCT04684498
Start Date
March 1 2020
End Date
March 31 2024
Last Update
December 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030